metsera.com - MTSR Net Assets per Single Share

Graphic logo of Metsera Inc (MTSR)

The Metsera Inc (MTSR) price chart helps assess the impact of geopolitical risks and logistics disruptions on the company developing obesity treatments. The current indicator stands at 3.19. The business's investment potential relies on the success of innovative metabolic research, regardless of macroeconomic conditions. Furthermore, ownership of a unique formula ensures colossal growth driven by low-cost production and global market reach.

Metsera, Inc. (MTSR): Share Book Value from 02/01/2025 to 11/29/2025

metsera.com - analytical breakdowns and key metrics (MTSR)

Key analytical indicators for Metsera (MTSR):
Price Chart Metsera Corp|MTSR - Analyst Median Target|Market Value Metsera Inc|MTSR - Value Adjusted for Debt and Cash|Net Assets per Single Share Metsera|MTSR - Net Asset Value|Market Capitalization to Book Value Ratio metsera.com|MTSR - Aggregate Asset Value|Total Debt to Capital Metsera Inc|MTSR - Long-Term Debt to Capital|Short-Term Debt to Equity Metsera|MTSR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Metsera Inc
Fundamental company valuation:Metsera Corp - MTSR
Manufactured products of Metsera

The market views Metsera Inc (MTSR) as a promising player in the obesity treatment sector. This metric is calculated by dividing equity by the number of shares, determining the investor's share of net assets. The price action of the book value per share reflects the actual capitalization of assets minus liabilities. For a company with inelastic demand for peptides, this indicator confirms the resource base necessary to compete with industry behemoths. The asset belongs to the class of high-tech biopharmaceutical securities.

Competitors of Metsera Inc (MTSR)

Net Assets per Single Share ASND (Ascendis Pharma Inc.)|MDGL: Net Assets per Share|Net Assets per Single Share Corcept Therapeutics CORT|RYTM (rhythmtx.com) - Accounting Value of a Share|Net Assets per Single Share Akero AKRO|Share Book Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Book Value per Share|Accounting Value of a Share NewAmsterdam Pharma Corp (NAMS)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS